We are laser-focused on our mission: to improve the lives of patients and their families.

Clinical Trials

Our pipeline programs target kidney diseases of high unmet need, including ADPKD.

Programs

We are targeting the underlying biology of these diseases with a novel and potentially powerful approach: MicroRNA-based therapeutics.

Technology

News.

November 22, 2023

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 9, 2023

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

November 2, 2023

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

MORE NEWS